OBJECTIVE (1) To determine an alternative iron supplementation with better efficacy, compliance & safety in treatment of iron deficiency anemia during pregnancy, (2) to reduce blood transfusion during pregnancy, labor and puerperium. MATERIAL AND METHOD A prospective comparative study. A total number of 60 pregnant women with the gestational age of 12-34 weeks were included in the study who w...

The impact of coexposure to a novel olfactory stimulation in combination with sweet taste on the construction of perceptual interaction was studied. The first objective was to explore whether a new flavoring perceived retronasally at a subthreshold concentration could enhance the perceived sweetness after a coexposure with sucrose using an approach encouraging associative learning. After valida...

BACKGROUND The clinical need to be able to administer high doses of intravenous iron conveniently in a single rapid infusion has been addressed by the recent introduction of ferric carboxymaltose and subsequently iron isomaltoside 1000. Neither requires a test dose. Ferric carboxymaltose can be administered at 15 mg/kg body weight to a maximum dose of 1000 mg, whereas iron isomaltoside 1000 can...

Emerging data from global markets outside the United States, where many generic iron sucrose formulations are available, have revealed that non-US generic intravenous (i.v.) iron formulations may have iron release profiles that differ from the reference listed drug (RLD). The first generic i.v. iron approved in the United States was sodium ferric gluconate complex in 2011. We evaluated chelatab...